Sibel Health

Sibel Health's Solutions

Sibel Health offers a range of advanced solutions tailored for various healthcare needs, including clinical trials and research, clinical care, sleep diagnostics, and remote patient monitoring. Their innovative approach leverages wireless sensors and wearable devices to provide real-time health data and insights. This allows for proactive monitoring and intervention, enhancing patient outcomes and operational efficiency in healthcare settings. With a strong focus on neonatal care, maternal health, adult care, and hospital-at-home solutions, Sibel Health aims to revolutionize global health.

Sibel Health's Wearable Devices

Sibel Health provides a suite of wearable devices designed to capture detailed physiological data. The ANNE® Chest sensor measures heart rate, respiratory rate, temperature, body position, and activity, while the ANNE® Limb sensor tracks SpO2 pulse rate, perfusion index, and skin temperature. The ADAM sensor offers comprehensive physiological monitoring with built-in BLE radio, electronics, and a rechargeable battery. These devices are integral to the company's solutions for continuous, real-time health monitoring, ensuring accurate and reliable data collection.

Sibel Health's Global Impact

Headquartered in Chicago, IL, with an additional office in Seoul, South Korea, Sibel Health has a significant global footprint. More than 5,000 of their systems have been deployed across over 20 countries, monitoring over 15,000 patients worldwide. Their commitment to advancing global health is evident through initiatives such as the $17.5 million grant from the Bill & Melinda Gates Foundation, aimed at improving maternal health monitoring in low-and-middle-income countries. This global presence underscores the company's mission to enhance healthcare accessibility and quality on a worldwide scale.

Sibel Health's FDA-Cleared Products

Sibel Health has achieved notable regulatory milestones with their ANNE® One wireless monitoring solution, which is FDA-cleared for labor triage and continuous maternal health monitoring. The company's commitment to rigorous validation is further demonstrated by their fourth FDA clearance for continuous wearable vital signs monitoring with ANNE® One. These clearances signify the reliability and clinical efficacy of Sibel Health's products, reinforcing their position as a leader in the field of wearable health technology.

Sibel Health's Funding and Research

Sibel Health has successfully raised $33 million in Series B funding, highlighting investor confidence in their innovative healthcare solutions. Their technology has been validated in peer-reviewed publications, ensuring its scientific credibility and effectiveness. The Discovery platform, which is HIPAA and GDPR compliant, provides a robust framework for clinical trials, offering full traceability and comprehensive physiological monitoring. This strong foundation of funding and research enables Sibel Health to continue advancing their technologies and expanding their impact in the healthcare industry.